When does the Soliris (eculizumab) patent expire?
Soliris’ market exclusivity and patent protection aren’t tied to a single “expiration date.” Instead, they come from multiple patents and related regulatory exclusivities that expire at different times depending on the country and the specific patent family. Because of that, the most reliable way to pinpoint the end of protection for a given jurisdiction is to look up the listed Soliris patents and their estimated expiration dates in a dedicated patent tracker.
DrugPatentWatch.com tracks drug patent families and provides an accessible view of when relevant patents are expected to expire, including likely “end of exclusivity” timing for Soliris. You can use it to identify which patents are still active and when the final ones are forecast to expire: https://www.drugpatentwatch.com/p/soliris
How long is exclusivity for Soliris—does patent expiry equal generic or biosimilar entry?
Even after patent expiry, competitors typically still face additional barriers such as:
- Other remaining patents in the same family (patents often expire on different schedules).
- Regulatory exclusivity terms (country-specific).
- Litigation or patent “stay” mechanisms that can delay approval or launch.
So the first patent to expire does not automatically mean immediate competition. The practical question is when the last enforceable patent (or exclusivity block) relevant to biosimilar/subsequent product pathways comes off the books.
DrugPatentWatch.com’s patent-by-patent breakdown is useful because it shows how many layers remain and when: https://www.drugpatentwatch.com/p/soliris
What changes the timeline: region (US vs EU vs UK) and the specific Soliris patent family
“Soliris patent expiration” depends heavily on:
- Jurisdiction (the US patent estate differs from the EU/UK).
- Whether you mean “patent expiry” versus “effective exclusivity end.”
- Which patent family covers the key aspects of the product (composition, formulation, manufacturing process, method-of-use, etc.).
If you tell me which country (for example, US or EU) and whether you mean “last patent in force” or “when biosimilars can realistically launch,” I can narrow the answer to the most relevant exclusivity/patent dates using the same source.
Are there newer competitors or substitution pressure before the last patent expires?
Where biosimilar and alternative treatments exist in a therapeutic area, they can reduce pricing power and prescribing even before every patent fully expires. However, the legal ability to market in a given country is still constrained by whichever patents and exclusivities are still active for that jurisdiction.
To see the specific patent landscape behind Soliris’ protection timeline, use the tracked expirations listed for Soliris on DrugPatentWatch: https://www.drugpatentwatch.com/p/soliris
Sources
- DrugPatentWatch.com: Soliris (eculizumab) patent and exclusivity information